10-Q: Akari Therapeutics Faces Going Concern Doubt Amid Q3 Losses

Akari Therapeutics reported substantial losses and a going concern warning for Q3 2025, despite a strategic shift to its ADC platform and recent capital raises.

Summary

• Akari Therapeutics reported a net loss of $6.4 million for the three months ended September 30, 2025, compared to $2.9 million for the same period in 2024.
• The net loss for the nine months ended September 30, 2025, was $12.0 million, an improvement from $16.0 million in the prior year period.
• Cash balance stood at $2.5 million as of September 30, 2025, which is insufficient to fund operations for the next year, raising substantial doubt about the company's ability to continue as a going concern.
• The company recorded a $5.18 million impairment loss on its PHP-303 intangible asset due to reprioritization of resources to its ADC platform and inability to find a collaborative partner.
• Research and development expenses decreased significantly to $1.7 million for the nine months ended September 30, 2025, from $5.7 million in the prior year, reflecting the suspension of legacy programs.
• General and administrative expenses increased to $7.1 million for the nine months ended September 30, 2025, from $6.6 million in the prior year, primarily due to non-cash stock-based compensation and professional fees.
• Akari completed a registered direct offering on October 16, 2025, raising $2.5 million in gross proceeds.
• The company entered into an Ordinary Share Purchase Agreement with White Lion Capital, LLC on August 29, 2025, for up to $25 million in equity, subject to conditions.
• Unsecured promissory notes were issued in August 2025 to certain investors, including directors, for an aggregate purchase price of $3.011 million.

Sentiment

Score: 2

Explanation: The company faces severe financial distress with a 'going concern' warning, significant losses, and ineffective internal controls. While there's a strategic pivot and recent capital raises, these are primarily for survival and do not yet indicate a stable or profitable future. The impairment loss further highlights challenges.

Positives

• Net loss for the nine months ended September 30, 2025, decreased to $12.0 million from $16.0 million in the prior year, indicating some cost control.
• Research and development expenses decreased by $4.0 million for the nine months ended September 30, 2025, due to the strategic reprioritization of programs.
• The company recognized a gain on settlement of current liabilities of $0.8 million for the three months and $2.0 million for the nine months ended September 30, 2025.
• Successful completion of a $2.5 million registered direct offering in October 2025 and securing an equity line of credit for up to $25 million with White Lion Capital, LLC, providing potential future funding.

Negatives

• The company reported a substantial net loss of $6.4 million for the three months ended September 30, 2025, a significant increase from $2.9 million in the prior year period.
• Cash balance of $2.5 million as of September 30, 2025, is insufficient to fund operations for the next 12 months, leading to a 'going concern' warning.
• An impairment loss of $5.18 million was recognized on the PHP-303 intangible asset, indicating a write-down of a previously acquired asset.
• Total current liabilities ($15.568 million) significantly exceed total current assets ($2.946 million) as of September 30, 2025.
• Disclosure controls and procedures were deemed 'not effective' as of September 30, 2025, due to material weaknesses in internal control over financial reporting, with remediation efforts not yet commenced.
• The company continues to incur substantial operating losses and negative cash flows from operations.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to recurring losses and insufficient cash to fund operations for the next year.
• Dependence on outside sources of capital; no assurance that future funding efforts (equity/debt financings, collaborations) will be successful or available on acceptable terms.
• Uncertainty of product development and generation of revenues, as the company is a pre-clinical and clinical stage company with no commercialized products.
• Risks associated with clinical trials of products, dependence on third-party collaborators for R&D, and the need for marketing authorization.
• Risks associated with protection of intellectual property and competition with larger, better-capitalized companies.
• Potential for dilution to existing shareholders from future equity or convertible debt financings.
• Increased fixed obligations and restrictive covenants if indebtedness is incurred.
• Material weaknesses in internal control over financial reporting, leading to ineffective disclosure controls and procedures, which could impact financial reporting reliability.

Future Outlook

The company anticipates incurring additional losses until it can generate significant sales of its product candidates, which are currently in research and development. Substantial additional financing will be needed to fund future operations, and management is evaluating various strategies including equity/debt offerings and strategic collaborations. The company's existing cash, combined with funds from the October 2025 financing, is expected to fund operations only into December 2025. The ability to generate revenue and achieve profitability depends on the successful development and commercialization of potential therapies, which is expected to take several years.

Management Comments

• Management concluded that disclosure controls and procedures were not effective at a reasonable assurance level as of September 30, 2025, due to previously identified material weaknesses in internal control over financial reporting.
• Management expects to begin remediation efforts for internal control weaknesses during the third quarter and continue through fiscal year 2025.
• Management believes the remediation steps disclosed in the Form 10-K will address deficient controls and facilitate remediation of material weaknesses.

Industry Context

Akari Therapeutics is pivoting its strategy within the highly competitive oncology biotechnology sector, shifting from legacy programs to focus on next-generation Antibody-Drug Conjugates (ADCs). This move aligns with a broader industry trend towards targeted cancer therapies. However, the company is in a pre-clinical stage with its lead ADC candidate (AKTX-101), placing it at an early and high-risk phase compared to many established players or those with late-stage clinical assets. Its financial instability and 'going concern' warning highlight the significant capital demands and inherent risks of drug development, particularly for smaller biotech firms relying heavily on external financing.

Comparison to Industry Standards

• The company's pre-clinical stage ADC platform (AKTX-101) is focused on Trop2-targeting, a crowded but high-potential area in oncology. Competitors with approved or advanced Trop2 ADCs include Gilead Sciences (Trodelvy/sacituzumab govitecan) and Daiichi Sankyo/AstraZeneca (Enhertu/trastuzumab deruxtecan, though primarily HER2, also has Trop2 potential). Akari aims for 'best-in-class' with its novel PH1 payload, but this is a high bar given the established efficacy and safety profiles of existing therapies.
• The significant accumulated deficit and 'going concern' warning are below industry standards for financial stability, particularly for companies seeking to advance multiple drug candidates. Many comparable early-stage biotech companies, while often unprofitable, typically maintain a longer cash runway or more robust financing pipelines to avoid such immediate liquidity concerns.
• The reported impairment loss on the PHP-303 asset reflects a common challenge in drug development where programs are deprioritized or discontinued due to strategic shifts or lack of partnership interest, similar to decisions made by larger pharmaceutical companies like Pfizer or Merck in their R&D portfolios.

Management Changes

Corporate Governance

Legal Proceedings

• A former employee of Peak Bio CA, Inc. subsidiary filed a claim for discretionary bonuses totaling less than $0.1 million; the company denies the claim and intends to defend itself.
• Settlement agreements were signed with two former consultants for wrongful termination claims, requiring a total payment of $0.4 million in monthly installments through November 2025 and continued vesting of restricted stock units.
• A lawsuit filed by Sabby Volatility Warrant Master Fund Ltd. for alleged breach of contract regarding a warrant exercise was settled on May 7, 2025, by issuing 272,450 ADSs to Sabby.

Related Party Transactions

• Dr. Hoyoung Huh (Chairman): In March 2025, $1.0 million of his notes (2021 Notes and part of January 2024 Note) were cancelled and extinguished in exchange for Ordinary Shares and warrants. In September 2025, he purchased an August 2025 Note ($1.25 million principal for $1.0 million purchase price) by cancelling $837,433 of his January 2024 Note and paying $162,567 cash. His Series A Warrants expiration dates were also extended. An amount due to an entity where Dr. Huh is a director (less than $0.1 million) is included in accounts payable.
• The Doctors Laboratory (TDL): The company leased office space and received administrative services from TDL, an entity with a common director, incurring less than $0.1 million in expenses for both the three and nine months ended September 30, 2025.
• Dr. Samir Patel (former CEO) and Dr. Ray Prudo (former Chairman): In May 2024, they entered into convertible promissory notes for an aggregate of $1.0 million. $750,000 was repaid in cash, and the remaining $250,000 was converted into the company's ADSs.

Stakeholder Impact

• Shareholders: Face significant dilution risk from ongoing and future equity capital raises, as well as potential loss of investment due to the 'going concern' doubt and accumulated deficit. The increase in authorized shares facilitates further dilution.
• Employees: Impacted by the reduction-in-force in May 2024 and the suspension of legacy programs, indicating job insecurity and strategic shifts in R&D focus. Stock-based compensation is a significant component of overall compensation.
• Creditors: Convertible noteholders and other debt holders are subject to the company's liquidity challenges and the risk of default, although some debt has been settled or converted.
• Customers (potential): Future customers for ADC therapies face uncertainty regarding product development timelines and eventual commercialization given the company's early stage and financial constraints.
• Management: Under pressure to secure funding, execute the strategic pivot to ADCs, and remediate internal control weaknesses, with compensation partly tied to stock-based awards and capital raises.

Next Steps

• Continue research and development activities for the ADC platform, with a focus on AKTX-101.
• Seek strategic partners to advance the development of legacy programs (nomacopan, PAS-nomacopan, PHP-303) externally.
• Raise additional capital through equity/debt financings or strategic collaborations to fund future operations.
• Begin implementing remediation efforts to address material weaknesses in internal control over financial reporting during Q3 and continue through fiscal year 2025.
• File a registration statement on Form S-1 with the SEC within 30 days following August 29, 2025, to register the resale of shares under the White Lion ELOC Purchase Agreement.

Key Dates

Recommendation

Akari Therapeutics is in a precarious financial position, evidenced by its 'going concern' warning, substantial accumulated deficit, and insufficient cash runway. The company's disclosure of ineffective internal controls further undermines investor confidence. While the strategic pivot to the ADC platform and recent capital raises offer a lifeline, the company remains in a high-risk, pre-clinical stage, requiring significant future funding and facing intense competition. The continuous dilution of existing shareholders through equity offerings and the inherent uncertainties of drug development make this a highly speculative and risky investment, warranting a 'strong sell' recommendation.

Keywords

Akari Therapeutics, AKTX, Antibody-Drug Conjugates, ADC platform, Oncology, Cancer therapy, Pre-clinical development, Going concern, SEC filing, 10-Q, Biotechnology, Pharmaceuticals, Capital raise, Warrants, Convertible notes, Financial results, Research and development, Impairment loss, Corporate governance, Internal controls